Noida, India

Rajendra Kristam

USPTO Granted Patents = 5 


Average Co-Inventor Count = 9.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2014-2017

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Rajendra Kristam

Introduction

Rajendra Kristam is a notable inventor based in Noida, India. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on pyridine derivatives. With a total of five patents to his name, Kristam's research focuses on developing compounds that can effectively treat conditions associated with abnormal cellular proliferation, including cancer.

Latest Patents

Among his latest patents, Kristam has developed novel pyridine compounds and their pharmaceutically acceptable salts or prodrugs. These compounds are designed to inhibit CYP17 activity, which is crucial in treating various diseases characterized by abnormal cellular proliferation. Notably, one of the diseases targeted by these compounds is prostate cancer. The methods for preparing these compounds are also outlined in his patent applications, showcasing their potential therapeutic applications.

Career Highlights

Rajendra Kristam is currently associated with Asana Biosciences, LLC, where he continues to advance his research in pharmaceutical innovations. His work has garnered attention for its potential impact on cancer treatment and other related conditions.

Collaborations

Kristam collaborates with esteemed colleagues, including Roger Astbury Smith and Nicholas James Laping, who contribute to the innovative environment at Asana Biosciences.

Conclusion

Rajendra Kristam's contributions to the field of pharmaceuticals through his innovative patents highlight his commitment to advancing medical science. His work on pyridine derivatives represents a significant step forward in the treatment of cancer and other diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…